stock decline

FTC sues Zillow and Redfin for alleged rental advertising collusion; Zillow stock drops 4.6% as law firm launches shareholder investigation.

FDA rejected Disc Medicine's bitopertin drug application on February 13, 2026, triggering a 22% stock plunge. The Rosen Law Firm investigates potential securities claims for affected shareholders.

ImmunityBio faces class action lawsuit alleging false Anktiva claims. Stock plummeted 21% after FDA warning letter. Lead plaintiff deadline May 26, 2026.

Eli Lilly's new weight-loss drug Foundayo recorded just 3,707 prescriptions in week two, trailing Novo Nordisk's Wegovy by over 400%, triggering a 4% stock decline.

Soleno Therapeutics faces class action lawsuit over safety concerns and inflated metrics for flagship drug VYKAT™ XR. Stock plunged 27% following August short report and November earnings disappointment.

HCA Healthcare reported Q1 earnings matching expectations, but respiratory admissions fell 42% and ER visits dropped 32%, triggering a 9% stock sell-off.

Gemini Space Station faces securities fraud class action over IPO misstatements. Stock plummeted 79% following February restructuring and executive departures. Lead plaintiff deadline: May 15, 2026.

TotalEnergies approved $1.2B investment in Mirny wind-battery project in Kazakhstan with 75% external funding, but stock declined 0.80% amid tech-led market rally.

Air Products ($APD) stock tumbled 9.45% following merger negotiations with Yara International, as investors worry about integration complexity and capital demands.

DNOW Inc. shares crashed 19.1% following disappointing Q4 2025 results. Legal firm investigating potential securities claims and pursuing class action lawsuit.

Tesla shares fell 3.47% April 23 despite Q1 earnings beat and 16% sales growth, as $25B 2026 capex guidance for AI and robotics sparked investor concerns.

Class action lawsuit filed against $UPST alleging AI Model 22 overstated accuracy and overreacted to economic signals, triggering 9.7% stock decline after missed guidance.

Law firm launches shareholder investigation into $NANOX following $33.4M Q4 loss, $17.5M asset impairment, and CFO departure.

ServiceNow stock dropped 17.56% despite meeting earnings, as weaker-than-expected gross margin guidance raised concerns about SaaS pricing power amid AI disruption and deal delays.

Nike's 62.7% stock decline boosted its dividend yield to 3.5%, ranking third in the Dow, but free cash flow can't cover dividends and valuation remains expensive.

Lululemon names Nike executive Heidi O'Neill as new CEO, but stock plummets 11.76% on weak 2026 guidance despite beating earnings expectations.

TSCO stock plunged 11% after Q1 earnings missed targets due to lower operating income and customer traffic declines, though margins held and guidance was reaffirmed.

ServiceNow beat Q1 earnings, raising guidance by $205M, but stock plunged 14% after CFO warned Middle East tensions could delay deal closures.

Lufax faces class action lawsuit after firing auditor PwC, who flagged undisclosed related-party transactions and balance sheet overstatements since mid-2023.

ImmunityBio faces securities lawsuit after FDA warning over misleading Anktiva cancer claims. Stock drops 21%, erasing $2B market cap.